Prolonged remission of a demyelinating neuropathy in a patient with lymphoma and Sjögren's syndrome after Rituximab therapy.
J Clin Neuromuscul Dis
; 11(3): 127-31, 2010 Mar.
Article
em En
| MEDLINE
| ID: mdl-20215986
ABSTRACT
Chronic acquired demyelinating polyneuropathies may be refractory to conventional therapy including corticosteroids, plasma exchange, and intravenous immunoglobulin (Ig) or require long-term immunotherapy to maintain remission. Use of alternative approaches such as Rituximab, an anti-CD20 antibody, in the treatment of demyelinating polyneuropathy, unrelated to IgM gammopathy and myelin-associated glycoprotein antibodies, has been the subject of only a few case reports. We report the case of a 79-year-old woman with a distal acquired demyelinating polyneuropathy in the context of Sjögren's syndrome, IgG paraproteinemia, and occult lymphoma who has had an excellent and durable response to Rituximab therapy.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Fatores Imunológicos
/
Anticorpos Monoclonais
Limite:
Aged
/
Female
/
Humans
Idioma:
En
Revista:
J Clin Neuromuscul Dis
Ano de publicação:
2010
Tipo de documento:
Article